Cullinan Therapeutics Inc [CGEM] stock prices are up 6.78% to $8.19 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CGEM shares have gain 6.92% over the last week, with a monthly amount drifted -1.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with a Outperform. Wedbush started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
The stock price of Cullinan Therapeutics Inc [CGEM] has been fluctuating between $6.85 and $19.89 over the past year. Currently, Wall Street analysts expect the stock to reach $31.5 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $8.19 at the most recent close of the market. An investor can expect a potential return of 284.62% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.37 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.86 points at the first support level, and at 7.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.42, and for the 2nd resistance point, it is at 8.65.
Ratios To Look Out For
It’s worth pointing out that Cullinan Therapeutics Inc [NASDAQ:CGEM]’s Current Ratio is 9.83. On the other hand, the Quick Ratio is 9.83, and the Cash Ratio is 2.6.
Transactions by insiders
Recent insider trading involved Jones Jeffrey Alan, Chief Medical Officer, that happened on Feb 25 ’25 when 4895.0 shares were sold. President and CEO, AHMED NADIM completed a deal on Feb 25 ’25 to sell 12529.0 shares. Meanwhile, Chief Scientific Officer Michaelson Jennifer sold 3756.0 shares on Feb 25 ’25.